Model AZD4604 - Phase I - Asthma

Mechanism: Inhaled JAK1 inhibitor, Area under investigation:asthma, Date commenced phase: Q4 2021, Estimated Filing Acceptance: Country: US: EU: Japan: China. Additional information: Molecule size: Small molecule Status change